Key Highlights
- Insamo has raised $12 million in seed funding from notable investors, including Playground Global, venBio, and MRL Ventures Fund.
- The funding will support the development of membrane-permeable, orally available cyclic-peptides.
- AI and machine learning technologies drive the platform’s ability to rapidly identify promising preclinical candidates.
Source: Business Wire
Notable Quotes
- “Insamo’s mission is to transform how we discover drugs for some of the most challenging diseases,” – Timothy Craven, CEO and co-founder at Insamo
- “Insamo represents Playground’s commitment to investing in companies that apply proprietary data for AI and machine learning in underexplored domains,” – Matt Hershenson, Co-founder at Playground Global
- “This innovative platform truly discovers membrane-permeable cyclic-peptides with oral bioavailability,” – Dr. Corey Goodman, Co-founder at venBio
SoHC's Take
Insamo’s recent seed funding milestone is a testament to the growing interest in leveraging advanced AI and machine learning technologies for drug discovery. The company’s focus on developing membrane-permeable and orally available cyclic-peptides represents a significant innovation in the field. By combining ML-driven molecular design with high-throughput molecular biology and synthetic chemistry, Insamo is poised to make substantial advancements in the development of treatments for diseases once considered untreatable.
The involvement of seasoned investors and industry veterans on Insamo’s board signifies a strong belief in the company’s mission and technology. As Insamo embarks on its journey to revolutionize drug discovery, the biotech community eagerly awaits the breakthroughs that will emerge from its platform. Insamo’s success could pave the way for new paradigms in the development of oral therapeutics, offering hope for patients with complex diseases requiring novel treatment options.
